FDA Takes Step Toward Allowing ANDAs For Zometa
The U.S. Food and Drug Administration has determined that Novartis AG's bone cancer drug Zometa was not withdrawn from sale for reasons of safety or effectiveness, paving the way for generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article